The research, conducted by an experienced clinical team, tracked outcomes for patients undergoing large-bore venous access procedures, including pulsed field ablation for atrial fibrillation and left atrial appendage closure. Data revealed a median time to hemostasis of just two minutes, with 92.5% of patients discharged on the same day as their procedure. The median discharge time for this cohort was 3.5 hours, with an overall vascular complication rate of 1.2% and no requirement for surgical intervention.
In section Releases
Study Validates VASCADE MVP XL for Large-Bore Venous Procedures
A retrospective study of 1,623 patients at Emory University has provided new evidence for the VASCADE MVP XL venous vascular closure system. The findings, published following the device's recent FDA label expansion, confirm the system's ability to achieve rapid hemostasis and enable same-day discharge in complex electrophysiology procedures.
Dr. David B. De Lurgio, the study's corresponding author and professor of medicine at Emory University, highlighted that same-day discharge was consistently achieved even when using sheaths larger than those typically associated with device-based closure. The study reinforces the utility of the system across a broad patient population, including those with significant comorbidities. This evidence follows the March 2026 FDA approval, which expanded the system's labeling to include procedures using up to 17F outer diameter procedural sheaths, covering market-leading technologies from Abbott, Boston Scientific, and Medtronic.
Comments (0)
No comments yet. Be the first!